UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 10-K
|
[X]
|
ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
|
|
| For the fiscal year ended December 31, 2009 | ||
| [ ] | TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT | |
| For the transition period from _________ to ________ | ||
| Commission file number: 000-25911 |
|
Skinvisible, Inc.
|
|
|
(Exact name of registrant as specified in its charter)
|
|
|
Nevada
|
88-0344219
|
|
(State or other jurisdiction of incorporation or organization)
|
(I.R.S. Employer Identification No.)
|
|
6320 South Sandhill Road, Suite 10, Las Vegas, NV
|
89120
|
|
(Address of principal executive offices)
|
(Zip Code)
|
|
Registrant’s telephone number: 702.433.7154
|
|
|
Securities registered under Section 12(b) of the Exchange Act:
|
|
|
Title of each class
|
Name of each exchange on which registered
|
|
none
|
not applicable
|
|
Securities registered under Section 12(g) of the Exchange Act:
|
|
|
Title of each class
|
|
|
Common Stock, par value $0.001
|
|
Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes [ ] No [X]
Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes [ ] No [X]
Indicate by checkmark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceeding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes [X] No [ ]
Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceeding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes [ ] No [ ]
Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K (§ 229.405 of this chapter) is not contained herein, and will not be contained, to the best of registrant’s knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-K or any amendment to this Form 10-K. Yes [ ] No [X]
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act. [ ]
Large accelerated filer [ ] Accelerated filer [ ] Non-accelerated filer [ ] Smaller reporting company [X]
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes [ ] No [X]
State the aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant’s most recently completed second fiscal quarter. $120,360
Indicate the number of shares outstanding of each of the registrant’s classes of common stock, as of the latest practicable date. 95,042,509 as of January 31, 2010.
TABLE OF CONTENTS
|
Page
|
||
|
PART I
|
||
|
PART II
|
||
|
PART III
|
||
|
PART IV
|
||
2
PART I
Item 1. Business
Company Overview
We develop innovative polymer delivery vehicles and related compositions that hold active ingredients on the skin for extended periods of time when applied topically. We designed a process for combining water soluble and insoluble polymers that is specifically formulated to carry water insoluble active ingredients in water-based products without the use of alcohol, silicones, waxes, or other organic solvents. This enables active agents the ability to perform their intended functions for an extended period of time. Our polymer delivery vehicles, trademarked Invisicare®, allow normal skin respiration and perspiration. The polymer compositions we develop wear off as part of the natural exfoliation process of the skin's outer layer cells.
We believe Invisicare® offers the following benefits:
|
§
|
Displays superior skin adherence for extended time periods
|
|
§
|
Non-occlusive yet resists water wash-off, respiration and perspiration
|
|
§
|
Increased efficacy of active ingredients
|
|
§
|
Allows for lower use levels of actives with increased persistence of effect
|
|
§
|
Offers advantage of controlled and/or sustained time-release
|
|
§
|
Highly compatible with a variety of actives and bases
|
|
§
|
Easy to emulsify
|
|
§
|
Formulates well at a cream, lotion, or spray viscosity
|
|
§
|
Non-irritating emulsion dries quickly with no greasy after-feel
|
|
§
|
Non-occlusive film forms protective barrier against environmental irritants
|
|
§
|
Broad polymer selection to meet application requirements
|
|
§
|
Offers “Life Cycle” management to core products with potential for new patent
|
|
§
|
Simplified manufacturing process
|
Products that successfully incorporate Invisicare to date include antimicrobial hand sanitizer lotions, suncare products, skincare moisturizers, sunless tanning products as well as various dermatology products for various skin disorders. On an ongoing basis, we are seeking to develop polymer formulations that can successfully be incorporated into other products.
Our primary objective is to license Invisicare to established brand manufacturers and marketers of prescription and over-the-counter products in the dermatological, medical, cosmetic, and skincare markets. With the exception of sales to one vendor, our management’s policy is to only sell Invisicare to vendors that have executed a license agreement with us. We conduct our research and development in-house. We engage an outside party that currently handles all of our manufacturing and distribution needs.
Our Business
Our core business is the research and development of products formulated with our patented technology Invisicare. Our continued focus is on the licensing of these products and developing new Invisicare technologies. Our focus has allowed us to expand our reputation amongst key dermatology, consumer goods and medical/surgical companies around the globe. It has also allowed us to branch out beyond dermatology into other medical areas that require topically delivered products.
Our Products
We intend to expand our product offerings. Currently we have over 30 topical products formulated with Invisicare available for licensing. Our products range from acne formations to sunscreens to surgical products.
Licensing Opportunities
Patented delivery system enhances life cycle management of topical products
Skinvisible, developers of its polymer delivery system Invisicare® with numerous technology and product patents and patents pending, has the following product formulations available for licensing on an exclusive basis. Each product has achieved three year accelerated stability (120 days @ 40° C).
ACNE:
|
·
|
Adapalene Cream & Gel (.1%, .3%)*
|
|
·
|
Clindamycin Hydrochloride Cream (1%)*
|
|
·
|
Retinoic Acid Cream & Gel (0.1%)*
|
|
·
|
Salicylic Acid Cream (2%)
|
|
·
|
Benzoyl Peroxide Cream (2.5% TBD)
|
|
-
|
Delivered with a sustained release which also allows for more or less active to be released over a longer period of time;
|
|
-
|
Reduced skin irritation from most actives;
|
|
-
|
Superior adherence; stays on the skin and does not rub off.
|
ACTINIC KERATOSIS:
|
·
|
Imiquimod Lotion (2%, 3%)*
|
|
-
|
Delivered with a controlled release which also allows for more or less active to be released (8% to 80%) than the branded product (10%) and over a longer period of time;
|
|
-
|
Binds to the skin resisting rub off.
|
ANTI-INFLAMMATORIES / ANALGESICS / ANTIPRURITICS:
|
·
|
Hydrocortisone Cream (.5%, 1%)
|
|
·
|
Triamcinolone / Acetonide (1%)*
|
|
·
|
Clobetasole Proprionate (0.05%)*
|
|
·
|
Betamethasone (1%)*
|
|
·
|
Pramoxine Cream (1%)
|
|
·
|
Menthol Spray / Roll-on / Cream (6%, 8%)
|
|
·
|
Ibuprofen Cream (5%, 10%)
|
|
-
|
Formulations enhanced with Invisicare have the advantage of sustained release and adherence thereby delivering long-lasting results;
|
|
-
|
ie/ Release of Pramoxine is 3 times the branded product with 20% greater adherence.
|
ANTI-FUNGALS:
|
·
|
Terbinafine Cream & Gel (1%)
|
|
·
|
Clotrimazole Cream (1%)
|
|
·
|
Naftifine Cream (1%)*
|
|
-
|
Formulated with sustained release to deliver efficacious results – ie/ Terbinafine cream can release over 4 times branded product;
|
|
-
|
Superior adherence properties.
|
ANTIMICORBIAL HAND SANITIZERS / ANTISEPTICS:
|
·
|
Triclosan Lotion (1%) & Nonoxynol-9 /Tomadol 901
|
|
·
|
First Aid Antiseptic Triclosan (1%) & Allantoin (1%)
|
|
·
|
Benzalkonium Chloride Lotion (0.13%)
|
|
·
|
Chlorhexidine Gluconate Lotion (4%)
|
|
·
|
Chlorhexidine Gluconate (2%) Pre-Surgical Prep
|
|
-
|
Antimicrobials bind to the skin for 4 hours even with multiple hand washings;
|
|
-
|
Anti-bacterial and anti-viral testing successfully completed on several formulations;
|
|
-
|
Pre-op preparation delivers on-going protection even with irrigation;
|
No staining or odor with chlorhexidine formulations.
ATOPIC DERMATITIS / SUPER MOISTURIZERS:
|
·
|
Non-Steroidal Atopic Dermatitis Cream Hyaluronic Acid (1%)
|
|
·
|
Skin Protectant Lotion with Allantoin (1%)
|
|
·
|
Ectoin Super Moisturizer
|
|
·
|
Urea Moisturizer (25% & 30%*)
|
|
-
|
Skinvisible’s creams and lotions hold on the skin while resisting wash-off and rub-off;
|
|
-
|
Invisicare polymers provide enhanced skin barrier function while still allowing the skin to breathe normally;
|
|
-
|
Formulations have a smooth, silky feel with no residual oily feeling;
|
|
-
|
Non-Steroidal Atopic Dermatitis Cream could be marketed with only a 510K in the United States and as a medical device in Canada. Some preliminary toxicity data is available.
|
UVA / UVB SUNSCREENS:
|
·
|
Parsol 1789 (Avobenzone) - SPF 15 / 30 / 50 Lotion
|
|
·
|
Tinosorb S – SPF 15 / 30 / 50 Lotion
|
|
-
|
Photo-stability studies showed a minimum of 8 hours for both Invisicare sunscreen formulations;
|
|
-
|
Sunscreens remain bound longer than popular brands even after perspiring and swimming ie/ Skinvisible’s avobenzone SPF 30 remained 81% bound after 2 hours versus leading brands showing only 50% to 73%. Skinvisible’s Tinosorb sunscreen remained 87% bound vs a leading brand with 64% bound.
|
OTHER:
|
·
|
Incontinence / Diaper Barrier Cream DPHP (1% Dipalmitoyl hydroxyproline)
|
|
-
|
Skinvisible’s DPHP cream provides a protease inhibitor and a polymer delivery system that binds to the skin, creates a non-occlusive barrier, and that is resistant to wash off or rubbed off;
|
|
-
|
Invisicare polymers provide an excellent barrier function even on their own.
|
|
·
|
Skin Barrier Cream (WorkGluv)
|
|
-
|
Studies show WorkGluv barrier function resists penetration of many noxious chemicals and can protect hands from irritant contact dermatitis.
|
|
·
|
Scar Lotion with Onion Bulb
|
|
-
|
Onion Bulb Extract diminishes the appearance of scars and lightens discoloration.
|
|
·
|
Fragrance – Long Lasting Gel
|
|
-
|
A scent incorporated with Invisicare provides a long lasting fragrance in a gel formulation.
|
|
·
|
Sunless Tanner – Long Lasting Lotions (2.5%, 5% & 9%)
|
|
-
|
Skinvisible sunless tanners remain on the skin for 7 days versus 3 days for branded formulas along with a darker, more uniform tan with no orange color and an improved odor.
|
|
·
|
After Sun (Aloe) Cream
|
|
-
|
Skinvisible’s After Sun Cream delivers soothing aloe to help relieve sunburn.
|
*prescription
SUMMARY OF INVISICARE BENEFITS:
|
·
|
Independent studies proved that Invisicare holds active ingredients on the skin for up to 4+ hours;
|
|
·
|
Studies prove it resists wash off even after multiple hand washing and perspiration;
|
|
·
|
Invisicare can improve the efficacy of topical active ingredients;
|
|
·
|
Non-drying as it does not contain alcohol and other ingredients that can occlude the skin;
|
|
·
|
It gradually releases active ingredients thereby reducing skin irritation;
|
|
·
|
The release of actives can be controlled by Invisicare; slow release to fast release of the active;
|
|
·
|
Skin barrier studies prove it is non-occlusive, forming a protective barrier while allowing the skin to function normally;
|
|
·
|
Skinvisible formulations have a simplified manufacturing process, requiring no special equipment;
|
|
·
|
Invisicare offers product life cycle management advantages (i.e. new patents).
|
In April 2009, we announced that we have developed a hand sanitizing lotion that has proven effective in killing the H1N1 swine flu virus. Retroscreen Virology of London England conducted the studies with our hand sanitizer lotion called DermSafe®. The product demonstrated it had a greater than 99.99 % inactivation/kill on the H1N1 swine flu virus.
We have a series of studies demonstrating that DermSafe kills a host of viruses and bacteria, including several influenza viruses such as H1N1 (“swine flu”), H3N2 and H5N1 (“avian bird flu virus”). The active ingredient in DermSafe is chlorhexidine gluconate, which has been used in hospitals worldwide for over fifty years as a pre-surgical hand scrub. DermSafe is available for licensing both commercially in healthcare and food services as well as for personal use (retail) worldwide. DermSafe has been approved for distribution by Health Canada and the company is implementing a plan to seek FDA approval in the US and worldwide.
To assist with our approvals in the US, Canada and Europe we are conducing further human studies on the H1N1 virus. We successfully completed a new clinical study proving that our hand sanitizer lotion DermSafe kills/inactivates the H1N1 virus on humans. This in-vivo study proves that DermSafe meets the criteria set-out by internationally accepted study guidelines to show efficacy against the H1N1 “swine flu” virus.
The study, performed at the independent testing laboratory Bioscience Laboratories, Inc., required that the subjects’ finger pads be contaminated with the H1N1 virus and then examined according to the American Society for Testing and Materials (ASTM) Standards. The results of the study proved that DermSafe killed the virus to the same detection level as 70% alcohol. In some countries, this study allows us to submit data for approval to include “Kills H1N1” on our product labels. This further confirms the efficacy of DermSafe as previously announced in an in-vitro study conducted at Retroscreen Virology, where DermSafe also achieved a 99.99% kill / inactivation of the H1N1 virus.
Furthermore, DermSafe was also successfully tested in an in-vivo bacterial hand disinfection study using the European Standard Method. This study method is used in a number of countries in Europe and also in Canada for approval in the healthcare and food services industries. The results proved the efficacy of DermSafe against bacteria on artificially contaminated hands as compared to the reference product of 60% isopropanol, a typical alcohol used in hand sanitizers.
License Agreements
Set forth below are our current licensees, along with their developed products that contain our Invisicare product or our own products with Invisicare in the territories provided:
|
Licensee
|
Product
|
Licensed Territories
|
Status of Current Territories Marketed
|
|
JD Nelson & Associates
|
Safe4Hours®, an antimicrobial hand sanitizer
|
US, Canada and Mexico
|
US and Canada
|
|
JD Nelson & Associates
|
first aid antiseptic skin protectant
|
US, Canada and Mexico
|
US
|
|
Sunless Beauty
|
Solerra® sunless tanning products
|
Global
|
Global
|
|
Panalab Internacional S.A.
|
acne prescription formulations with the active ingredient adapalene
|
Latin America
|
Completing regulatory approvals; expected to market Q3, 2010.
|
|
Embil Pharmaceuticals
|
prescription acne products (Clindamycin HCL and Retinoic Acid formulations)
|
Turkey parts of Asia (Indonesia, Malaysia, and the Philippines) and Azerbaijan, Kazakhstan, Kyrgyzstan, Turkmenistan, and Uzbekistan
|
Seeking regulatory approval; expected to market in 2011
|
|
RHEI Pharmaceuticals NV
|
first option to license the exclusive rights for Skinvisible's dermatology products
|
China, Hong Kong and Taiwan
|
Seeking regulatory approval
|
|
Mayquest Pharmaceuticals PTE. Ltd.
|
DermSafe
|
Singapore, Indonesia, the Philippines, Thailand and Malaysia
|
Received regulatory approval in Singapore to import and retail; seeking further approvals to sell commercially in Singapore and the balance of their territory
|
|
Alto Pharmaceuticals
|
DermSafe
|
Canada
|
Waiting for DIN approval for Commercial Use
|
Marketing Developments
In January 2010, one of our licensees, JD Nelson and Associates LLC, announced that it has entered into a distribution agreement with Walgreens for their new product, Safe4Hours®First Aid Antiseptic Skin Protectant. This new product uses our patented Invisicare® technology and was launched in 7,000 Walgreens stores on January 15, 2010. The product, available in both a one and two ounce size, promotes healing of minor cuts, scrapes and burns as well as preventing the spread of bacteria including the super bug MRSA, a real health issue in hospitals, schools and for participants in sports. The product also protects and helps relieve chafed, chapped or cracked skin (dermatitis) as well as prevents and protects from the drying effects of wind and cold weather. Walgreens features the product both in the first aid section of their stores as well as at the pharmacy counter.
In February 2010, JD Nelson and Associates LLC initiated a special marketing promotion in connection with the sale of Safe4Hours in Walgreens stores. The promotion includes prominent end-cap point of purchase displays which will profile Safe4Hours in 4,100 Walgreens. This heightened visibility along with a television advertising campaign is anticipated to educate consumers about the product’s benefits.
Patent Developments
We intend to continually generate new patents (intellectual property) on our Invisicare technology as well as on the dermatology and medical products we have formulated. To date we have received Patent approval for the Invisicare technology in the US (3), Australia, India, Japan and China with approvals expected shortly in Canada, Korea and Hong Kong. In addition to the Invisicare technology patent protection we also seek protection on certain finished product formulations initially in the US and then internationally. All patents with Invisicare are owned by Skinvisible.
Patent protection is important to our company. Pharmaceutical companies are pursuing new or improved revenue streams along with protecting their own intellectual properties. Invisicare allows companies to sell a patent-protected product that has been revitalized with new benefits, giving them a new story to help combat generic competitors. A prescription dermatology product can generate sales of $100 plus million per year; some even $200 plus million – and that is why we believe the investment into a license with an Invisicare formulation is a very viable option for these companies.
We continue to submit for patent protection worldwide for products formulated with Invisicare.
Status of Research and Development for New Applications
We believe that the enhancement and extension of our existing products and the development of new product categories have contributed significantly to our growth to date and are necessary for our continued growth. Our management evaluates new ideas and seeks to develop new products and improvements to existing products to satisfy industry requirements and changing consumer preferences. We seek to identify trends in consumer preferences and to generate new product ideas. Specific to the objective of generating new products, we are continuing our research and development toward developing additional applications with Invisicare.:
Competition
While there is significant competition in the skincare products industry, our primary business objective is to license our technology and formulated products to manufacturers of Rx and OTC skincare products. Market research undertaken to date has indicated that, at present, there is reasonably limited competition for our polymer-based delivery systems and related technologies such as delivery vehicles and technologies that offer the same performance capabilities for topically administered products. Some delivery technology companies offer a new way to bring active ingredients to the skin topically such as foam technology. This is usually where it stops as Invisicare not only offers this delivery but also offers a sustained or controlled release of the active ingredient from the emulsion – a real plus if the active ingredient causes skin irritation.
Trademarks
In January 2002, we received trademark approval in the United States for the name "Invisicare" to identify our family of polymer delivery systems. We have filed this trade name with the Cosmetic, Fragrance and Toiletries Association ("CFTA") as an ingredient for use in skincare and cosmetic formulations.
We have also applied and received trademark approval for the corporate logo “Skinvisible”.
We are seeking to extend the protection of our trademarks in additional countries where we currently conduct business and those additional countries where we intend to conduct business.
Employees
We currently have five employees, including our sole officer Terry Howlett. All our employees with the exception of our bookkeeper are full-time employees.
Research and Development Expenditures
We incurred research and development expenditures of $0 in the fiscal year ended December 31, 2009, and $21,780 in the fiscal year ended December 31, 2008.
Government Regulation
We are not subject to any significant or material federal or state government regulation in connection with the research and development and licensing of our innovative topical polymer-based delivery systems and technologies.
With respect to our products under development, our licensing agreements require the licensee to seek all required approvals for marketing, distribution, and sale in the jurisdictions for which it is desired to make the product available should we succeed in developing a successful product.
We are not subject to any significant or material environmental regulation in the normal operation of our business.
Subsidiaries
We conduct our operations through our wholly-owned subsidiary, Skinvisible Pharmaceuticals, Inc.
Item 2. Properties
Currently, we do not own any real estate. We are leasing our executive offices and research facility. We are located at 6320 South Sandhill Road, Suite 10, Las Vegas, Nevada 89120.
Skinvisible Pharmaceuticals, Inc., our wholly-owned subsidiary, owns the manufacturing and laboratory equipment at this location.
Item 3. Legal Proceedings
Jost Steinbrhchel and Monique Steinbruchel v. Skinvisible, Case No. 09A588041 in the District Court, Clark County Nevada.
Plaintiffs allege that we have not reimbursed Jost Steinbruchel for his expenses when he was a member of our board of directors and that Monica Steinbruchel loaned us $20,000 that has not been repaid. We are disputing these allegations.
Aside from the above, we are not a party to any pending legal proceeding. We are not aware of any pending legal proceeding to which any of our officers, directors, or any beneficial holders of 5% or more of our voting securities are adverse to us or have a material interest adverse to us.
Item 4. Submission of Matters to a Vote of Security Holders
No matters were submitted to a vote of our shareholders during the fourth quarter of our fiscal year ended December 31, 2009.
PART II
Item 5. Market for Registrant’s Common Equity and Related Stockholder Matters and Issuer Purchases of Equity Securities
Market Information
Our common stock is currently quoted on the OTC Bulletin Board (“OTCBB”), which is sponsored by FINRA. The OTCBB is a network of security dealers who buy and sell stock. The dealers are connected by a computer network that provides information on current "bids" and "asks", as well as volume information. Our shares are quoted on the OTCBB under the symbol “SKVI”
The following table sets forth the range of high and low bid quotations for our common stock for each of the periods indicated as reported by the OTCBB. These quotations reflect inter-dealer prices, without retail mark-up, mark-down or commission and may not necessarily represent actual transactions.
|
Fiscal Year Ending December 31, 2009
|
||||
|
Quarter Ended
|
High $
|
Low $
|
||
|
December 31, 2009
|
0.15
|
0.07
|
||
|
September 30, 2009
|
0.24
|
0.05
|
||
|
June 30, 2009
|
0.11
|
0.03
|
||
|
March 31, 2009
|
0.09
|
0.03
|
||
|
Fiscal Year Ending December 31, 2008
|
||||
|
Quarter Ended
|
High $
|
Low $
|
||
|
December 31, 2008
|
0.09
|
0.03
|
||
|
September 30, 2008
|
0.13
|
0.08
|
||
|
June 30, 2008
|
0.14
|
0.18
|
||
|
March 31, 2008
|
0.16
|
0.10
|
||
On March 1, 2010, the last sales price per share of our common stock was $0.11.
Penny Stock
The SEC has adopted rules that regulate broker-dealer practices in connection with transactions in penny stocks. Penny stocks are generally equity securities with a market price of less than $5.00, other than securities registered on certain national securities exchanges or quoted on the NASDAQ system, provided that current price and volume information with respect to transactions in such securities is provided by the exchange or system. The penny stock rules require a broker-dealer, prior to a transaction in a penny stock, to deliver a standardized risk disclosure document prepared by the SEC, that: (a) contains a description of the nature and level of risk in the market for penny stocks in both public offerings and secondary trading; (b) contains a description of the broker's or dealer's duties to the customer and of the rights and remedies available to the customer with respect to a violation of such duties or other requirements of the securities laws; (c) contains a brief, clear, narrative description of a dealer market, including bid and ask prices for penny stocks and the significance of the spread between the bid and ask price; (d) contains a toll-free telephone number for inquiries on disciplinary actions; (e) defines significant terms in the disclosure document or in the conduct of trading in penny stocks; and (f) contains such other information and is in such form, including language, type size and format, as the SEC shall require by rule or regulation.
The broker-dealer also must provide, prior to effecting any transaction in a penny stock, the customer with (a) bid and offer quotations for the penny stock; (b) the compensation of the broker-dealer and its salesperson in the transaction; (c) the number of shares to which such bid and ask prices apply, or other comparable information relating to the depth and liquidity of the market for such stock; and (d) a monthly account statement showing the market value of each penny stock held in the customer's account.
In addition, the penny stock rules require that prior to a transaction in a penny stock not otherwise exempt from those rules, the broker-dealer must make a special written determination that the penny stock is a suitable investment for the purchaser and receive the purchaser's written acknowledgment of the receipt of a risk disclosure statement, a written agreement as to transactions involving penny stocks, and a signed and dated copy of a written suitability statement.
These disclosure requirements may have the effect of reducing the trading activity for our common stock. Therefore, stockholders may have difficulty selling our securities.
Holders of Our Common Stock
As of December 31, 2009, we had 94,943,509 shares of our common stock issued and outstanding, held by 175 shareholders of record, other than those held in street name.
Dividends
We currently intend to retain future earnings, if any, to finance the expansion of our business. As a result, we do not anticipate paying any cash dividends in the foreseeable future.
In the event that a dividend is declared, common stockholders on the record date are entitled to share ratably in any dividends that may be declared from time to time on the common stock by our board of directors from funds legally available.
There are no restrictions in our articles of incorporation or bylaws that restrict us from declaring dividends. The Nevada Revised Statutes, however, do prohibit us from declaring dividends where, after giving effect to the distribution of the dividend:
|
|
1.
|
We would not be able to pay our debts as they become due in the usual course of business; or
|
|
|
2.
|
Our total assets would be less than the sum of our total liabilities, plus the amount that would be needed to satisfy the rights of shareholders who have preferential rights superior to those receiving the distribution.
|
Recent Sales of Unregistered Securities
The information set forth below relates to our issuances of securities without registration under the Securities Act of 1933 during the reporting period which were not previously included in a Quarterly Report on Form 10-Q or Current Report on Form 8-K.
During the three months ended December 31, 2009, we issued 400,429 restricted shares of our common stock as a result of entering into debt conversion agreements with lenders to convert total principal balances of $36,300 into equity.
During the three months ended December 31, 2009 we issued 1,083,335 restricted shares of our common stock as a result of entering into loan conversion agreements with lenders to convert total principal balances and interest of $65,000 into equity. In connection with the conversion, warrants were also granted to purchase 541,668 shares of our common stock at a strike price of $0.10 per share that expire on December 12, 2012.
During the three months ended December 31, 2009, we issued options to purchase 2,370,000 shares of our common stock at $0.08 per share under our 2006 Stock Option Plan to employees and consultants.
During the three months ended December 31, 2009, we issued Debt Conversion agreements to three employees, including Mr. Terry Howlett. The Debt Conversion agreements allow the holders to convert up to $161,933 in debt into shares of our common stock at $0.06 per share at any time up and until December 6, 2010. If the debt is converted into equity, these employees will be granted Warrant agreements for the right to purchase an aggregate of 1,214,442 shares of common stock at a strike price of $0.10 per share if exercised within 3 years of the debt conversion.
On April 21, 2009, we modified the exercise price on all of our outstanding options issued prior to March 31, 2009 to $0.04 per share.
These securities were issued pursuant to Section 4(2) of the Securities Act and/or Rule 506 promulgated thereunder. The holders represented their intention to acquire the securities for investment only and not with a view towards distribution. The investors were given adequate information about us to make an informed investment decision. We did not engage in any general solicitation or advertising. We directed our transfer agent to issue the stock certificates with the appropriate restrictive legend affixed to the restricted stock.
Securities Authorized for Issuance under Equity Compensation Plans
The following table provides information about our compensation plans under which shares of common stock may be issued upon the exercise of options as of December 31, 2009.
In July 2006, we adopted the 2006 Skinvisible, Inc. Stock Option Plan, which provides for the grant of incentive stock options, non-qualified stock options, stock appreciation rights, restricted stock, performance shares and performance units, and stock awards our officers, directors or employees of, as well as advisers and consultants. This plan was confirmed by our stockholders on August 7, 2006 at the annual shareholders meeting.
Under the 2006 Skinvisible, Inc. Stock Option Plan, we reserved 10,000,000 shares of common stock for the granting of options and rights.
Equity Compensation Plans as of December 31, 2009
|
A
|
B
|
C
|
|
|
Plan Category
|
Number of securities to be issued upon exercise of outstanding options, warrants and rights
|
Weighted-average exercise price of outstanding options, warrants and right
|
Number of securities remaining available for future issuance under equity compensation plans (excluding securities reflected in column (A))
|
|
Equity compensation plans
approved by security
holders
|
6,090,000
|
$0.05
|
3,910,000
|
|
Equity compensation plans
not approved by security
holders
|
11,136,847
|
$0.09
|
-
|
|
Total
|
17,226,847
|
3,910,000
|
Item 6. Selected Financial Data
A smaller reporting company is not required to provide the information required by this Item.
Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations
Forward-Looking Statements
Certain statements, other than purely historical information, including estimates, projections, statements relating to our business plans, objectives, and expected operating results, and the assumptions upon which those statements are based, are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements generally are identified by the words “believes,” “project,” “expects,” “anticipates,” “estimates,” “intends,” “strategy,” “plan,” “may,” “will,” “would,” “will be,” “will continue,” “will likely result,” and similar expressions. We intend such forward-looking statements to be covered by the safe-harbor provisions for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995, and are including this statement for purposes of complying with those safe-harbor provisions. Forward-looking statements are based on current expectations and assumptions that are subject to risks and uncertainties which may cause actual results to differ materially from the forward-looking statements. Our ability to predict results or the actual effect of future plans or strategies is inherently uncertain. Factors which could have a material adverse affect on our operations and future prospects on a consolidated basis include, but are not limited to: changes in economic conditions, legislative/regulatory changes, availability of capital, interest rates, competition, and generally accepted accounting principles. These risks and uncertainties should also be considered in evaluating forward-looking statements and undue reliance should not be placed on such statements. We undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise. Further information concerning our business, including additional factors that could materially affect our financial results, is included herein and in our other filings with the SEC.
Results of Operations for the Years Ended December 31, 2009 and 2008
Revenues
Our total revenue reported for the year ended December 31, 2009 was $287,269, a sharp decrease from $599,621 for the year ended December 31, 2008. The decrease in revenues for the year ended December 31, 2009 from the prior year is attributable to decreased sales of polymers to our licensees.
Cost of Revenues
Our cost of revenues for the year ended December 31, 2009 decreased to $51,462 from the prior year when cost of revenues was $101,061. The decrease in our cost of revenues for the year ended December 31, 2009 from the prior year is attributable to decreased sales of polymers.
Gross Profit
Gross profit for the year ended December 31, 2009 was $235,807, or approximately 82% of sales. Gross profit for the year ended December 31, 2008 was $498,560, or approximately 83% of sales.
Operating Expenses
Operating expenses increased to $1,633,791 for the year ended December 31, 2009 from $1,449,640 for the year ended December 31, 2008. Our operating expenses for the year ended December 31, 2009 consisted of depreciation and amortization expenses of $25,755 and selling, general and administrative expenses of $1,608,036. Our operating expenses for the year ended December 31, 2008 consisted of depreciation and amortization expenses of $194,144, and selling, general and administrative expenses of $1,255,496.
Other Expenses
We paid more in interest expenses for the year ended December 31, 2009 than in the prior year ended 2008, resulting in total other expenses of $349,712 as compared with $218,760 for the prior year.
Net Loss
Net loss for the year ended December 31, 2009 was $1,747,696 compared to net loss of $1,169,840 for the year ended December 31, 2008.
Liquidity and Capital Resources
As of December 31, 2009, we had total current assets of $52,383 and total assets in the amount of $244,407. Our total current liabilities as of December 31, 2009 were $1,093,969. We had a working capital deficit of $849,562 as of December 31, 2009.
Operating activities used $350,507 in cash for the year ended December 31, 2009. Our net loss of $1,747,696 combined with a decrease in accrued interest of $6,110 was the primary component of our negative operating cash flow, offset mainly by stock based compensation of $625,686, interest expense paid with common stock of $234,524, increase in accounts payable and accrued liabilities of $272,565, and decrease in prepaid royalty of $180,000. Cash flows used by investing activities during the year ended December 31, 2009 was $129,536. Cash flows provided by financing activities during the year ended December 31, 2009 amounted to $499,849 and consisted primarily of $168,485 as proceeds from the issuance of convertible notes payable, offset by payments of $2,136 on related party loans.
In order to preserve needed cash to operate our business, we have sought to and have been successful in converting certain of our debt into equity of our company. During the fourth quarter ended December 31, 2009, a total of $307,500, represented by loans, accrued compensation and expenses, has been converted into equity under various rates and terms. We can provide no assurance that we will be able to convert other debt in our company under similar arrangements, or at all, in the future. If we are unable to convert our debt into equity, or raise capital to cover our liabilities, we may not be able to continue as a going concern.
Based upon our current financial condition, we do not have sufficient cash to operate our business at the current level for the next twelve months. We intend to fund operations through increased sales and debt and/or equity financing arrangements, which may be insufficient to fund expenditures or other cash requirements. We plan to seek additional financing in a private equity offering to secure funding for operations. There can be no assurance that we will be successful in raising additional funding. If we are not able to secure additional funding, the implementation of our business plan will be impaired. There can be no assurance that such additional financing will be available to us on acceptable terms or at all.
Going Concern
The accompanying financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. We have incurred cumulative net losses of approximately $18,685,421 since our inception and require capital for our contemplated operational and marketing activities to take place. Our ability to raise additional capital through the future issuances of the common stock is unknown. The obtainment of additional financing, the successful development of our contemplated plan of operations, and our transition, ultimately, to the attainment of profitable operations are necessary for us to continue operations. The ability to successfully resolve these factors raise substantial doubt about our ability to continue as a going concern. Our consolidated financial statements do not include any adjustments that may result from the outcome of these aforementioned uncertainties.
Off Balance Sheet Arrangements
As of December 31, 2009, there were no off balance sheet arrangements.
Critical Accounting Policies
In December 2001, the SEC requested that all registrants list their most “critical accounting polices” in the Management Discussion and Analysis. The SEC indicated that a “critical accounting policy” is one which is both important to the portrayal of a company’s financial condition and results, and requires management’s most difficult, subjective or complex judgments, often as a result of the need to make estimates about the effect of matters that are inherently uncertain.
Revenue Recognition
Revenues are recognized during the period in which the revenues are earned. Costs and expenses are recognized during the period in which they are incurred.
Product sales - Revenues from the sale of products are recognized when title to the products are transferred to the customer and only when no further contingencies or material performance obligations are warranted, and thereby have earned the right to receive reasonably assured payments for products sold and delivered.
Royalty sales – The Company also recognizes royalty revenue from licensing its patent and trademarks, only when earned, with no further contingencies or material performance obligations are warranted, and thereby have earned the right to receive and retain reasonably assured payments.
Distribution and license rights sales – The Company also recognizes revenue from distribution and license rights only when earned, with no further contingencies or material performance obligations are warranted, and thereby have earned the right to receive and retain reasonably assured payments.
Costs of Revenue – Cost of revenue includes raw materials, component parts, and shipping supplies. Shipping and handling costs is not a significant portion of the cost of revenue.
Fixed Assets
Fixed assets are stated at cost less accumulated depreciation. Depreciation is provided principally on the straight-line method over the estimated useful lives of the assets, which are generally 3 to 10 years. The cost of repairs and maintenance is charged to expense as incurred. Expenditures for property betterments and renewals are capitalized. Upon sale or other disposition of a depreciable asset, cost and accumulated depreciation are removed from the accounts and any gain or loss is reflected in other income (expense).
We periodically evaluate whether events and circumstances have occurred that may warrant revision of the estimated useful life of fixed assets or whether the remaining balance of fixed assets should be evaluated for possible impairment. We use an estimate of the related undiscounted cash flows over the remaining life of the fixed assets in measuring their recoverability.
Goodwill and Intangible Assets
Beginning January 1, 2002, we adopted Statement of Financial Accounting Standards (“SFAS”) No. 142, “Goodwill and Other Intangible Assets”. According to this statement, goodwill and intangible assets with indefinite lives are no longer subject to amortization, but rather an annual assessment of impairment by applying a fair-value based test. Fair value for goodwill is based on discounted cash flows, market multiples and/or appraised values as appropriate. Under SFAS No. 142, the carrying value of assets are calculated at the lowest level for which there are identifiable cash flows.
SFAS 142 requires us to compare the fair value of the reporting unit to its carrying amount on an annual basis to determine if there is potential impairment. If the fair value of the reporting unit is less than its carrying value, an impairment loss is recorded to the extent that the fair value of the goodwill within the reporting unit is less than its carrying value. Upon adoption and during 2002, we completed an impairment review and did not recognize any impairment of goodwill and other intangible assets already included in the financial statements. We expect to receive future benefits from previously acquired goodwill over an indefinite period of time. Accordingly, beginning January 1, 2002, we have foregone all related amortization expense. Prior to January 1, 2002, we amortized goodwill over an estimated useful life ranging from 3 to 15 years using the straight-line method.
Recently Issued Accounting Pronouncements
In March 2008, the FASB issued SFAS No. 161, “Disclosures about Derivative Instruments and Hedging Activities – an amendment of FASB Statement No. 133,” (SFAS “161”) as amended and interpreted, which requires enhanced disclosures about an entity’s derivative and hedging activities and thereby improves the transparency of financial reporting. Disclosing the fair values of derivative instruments and their gains and losses in a tabular format provides a more complete picture of the location in an entity’s financial statements of both the derivative positions existing at period end and the effect of using derivatives during the reporting period. Entities are required to provide enhanced disclosures about (a) how and why an entity uses derivative instruments, (b) how derivative instruments and related hedged items are accounted for under Statement 133 and its related interpretations, and (c) how derivative instruments and related hedged items affect an entity’s financial position, financial performance, and cash flows. SFAS No. 161 is effective for financial statements issued for fiscal years and interim periods beginning after November 15, 2008. Early adoption is permitted.
At September 30, 2008, we did not have any derivative instruments or hedging activities. Management is aware of the requirements of SFAS 161 and will disclose when appropriate.
In May 2008, the FASB issued SFAS No. 162, “The Hierarchy of Generally Accepted Accounting Principles.” SFAS 162 will provide framework for selecting accounting principles to be used in preparing financial statements that are presented in conformity with U.S. generally accepted accounting principles (GAAP) for nongovernmental entities. SFAS 162 will be effective 60 days following the Securities and Exchange Commission’s approval of the Public Company Accounting Oversight Board (“PCAOB”) amendments to AU Section 411. We do not expect the adoption of SFAS 162 will have a material impact on our financial condition or results of operation.
In May 2008, the FASB issued SFAS No. 163, “Accounting for Financial Guarantee Insurance Contracts – an interpretation of FASB Statement No. 60.” SFAS 163 requires that an insurance enterprise recognize a claim liability prior to an event of default (insured event) when there is evidence that credit deterioration has occurred in an insured financial obligation. This Statement also clarifies how Statement 60 applies to financial guarantee insurance contracts, including the recognition and measurement to be used to account for premium revenue and claim liabilities. Those clarifications will increase comparability in financial reporting of financial guarantee insurance contracts by insurance enterprises. This Statement requires expanded disclosures about financial guarantee insurance contracts. The accounting and disclosure requirements of the Statement will improve the quality of information provided to users of financial statements. SFAS 163 will be effective for financial statements issued for fiscal years beginning after December 15, 2008. We do not expect the adoption of SFAS 163 will have a material impact on our financial condition or results of operation.
Item 7A. Quantitative and Qualitative Disclosures About Market Risk
A smaller reporting company is not required to provide the information required by this Item.
Item 8. Financial Statements and Supplementary Data
Index to Financial Statements Required by Article 8 of Regulation S-X:
|
Audited Financial Statements:
|
|
REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
To the Board of Directors
Skinvisible, Inc.
Las Vegas, Nevada
We have audited the accompanying consolidated balance sheet of Skinvisible, Inc. as of December 31, 2009 and 2008, and the related consolidated statements of operations, stockholders’ deficit, and cash flows for the years then ended. These consolidated financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on these consolidated financial statements based on our audit.
We conducted our audit in accordance with standards of the Public Company Accounting Oversight Board (United States). Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement. An audit includes examining, on a test basis, evidence supporting the amounts and disclosures in the consolidated financial statements. An audit also includes assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall consolidated financial statement presentation. We believe that our audit provides a reasonable basis for our opinion.
In our opinion, the consolidated financial statements referred to above present fairly, in all material respects, the financial position of Skinvisible, Inc. as of December 31, 2009 and 2008, and the consolidated results of its operations and cash flows for the years then ended in conformity with accounting principles generally accepted in the United States.
The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 1 to the financial statements, the Company has suffered recurring losses from operations, which raise substantial doubt about its ability to continue as a going concern. Management's plans regarding those matters also are described in Note 1. Absent the successful completion of one of these alternatives, the Company’s operating results will increasingly become uncertain. The financial statements do not contain any adjustments that might result from the outcome of this uncertainty.
Sarna & Company, CPA’s
April 8, 2010
Westlake Village, California
F-1
|
ASSETS
|
December 31, 2009
|
December 31, 2008
|
|||
|
(Audited)
|
(Audited)
|
||||
|
Current assets
|
|||||
|
Cash
|
$ | 25,868 | $ | 6,062 | |
|
Accounts receivable
|
468 | 9,553 | |||
|
Inventory
|
17,629 | 17,796 | |||
|
Due from related party
|
4,206 | 986 | |||
| Financing cost, net of accumulated amortization of $-0- and $344, respectively | -- | 55,562 | |||
|
Prepaid royalty fees - current portion
|
-- | 180,000 | |||
|
Prepaid expense and other current assets
|
4,212 | 4,182 | |||
|
Total current assets
|
52,383 | 274,141 | |||
|
Fixed assets, net of accumulated depreciation of $326,202 and $322,734, respectively
|
9,516 | 16,593 | |||
|
Intangible and other assets
|
|||||
| Patents and trademarks, net of accumulated amortization of $71,922 and $51,561, respectively | 132,508 | 23,333 | |||
|
License and distributor rights
|
50,000 | 50,000 | |||
|
Prepaid royalty fees - long term portion
|
-- | -- | |||
|
Total assets
|
$ | 244,407 | $ | 364,067 | |
|
LIABILITIES AND STOCKHOLDERS' DEFICIT
|
|||||
|
Current liabilities
|
|||||
|
Accounts payable and accrued liabilities
|
$ | 741,716 | $ | 469,151 | |
|
Accrued interest payable
|
17,099 | 23,209 | |||
|
Loans from related party
|
214,112 | 122,763 | |||
| Convertible notes payable, net of unamortized debt discount of $3,750 and $-0-, respectively | 71,250 | -- | |||
|
Unearned revenue
|
49,792 | 50,000 | |||
|
Total current liabilities
|
1,093,969 | 665,123 | |||
|
Total liabilities
|
1,093,969 | 665,123 | |||
|
Commitments and contingencies
|
-- | -- | |||
|
Stockholders' deficit
|
|||||
|
Common stock; $0.001 par value; 100,000,000 shares authorized 94,943,509 and
84,095,888 shares issued and outstanding at December 31, 2009 and 2008, respectively
|
94,945 | 84,098 | |||
|
Additional paid-in capital
|
17,740,914 | 16,552,571 | |||
|
Accumulated deficit
|
(18,685,421) | (16,937,725) | |||
|
Total stockholders' deficit
|
(849,562) | (301,056) | |||
|
Total liabilities and stockholders' deficit
|
$ | 244,407 | $ | 364,067 | |
See Accompanying Notes to Consolidated Financial Statements
|
for the year ended
|
|||||
|
December 31, 2009
(Audited) |
December 31, 2008
(Audited) |
||||
|
Revenues
|
$ | 287,269 | $ | 599,621 | |
|
Cost of revenues
|
51,462 | 101,061 | |||
|
Gross profit
|
235,807 | 498,560 | |||
|
Operating expenses
|
|||||
|
Depreciation and amortization
|
25,755 | 194,144 | |||
|
Selling general and administrative
|
$ | 1,608,036 | 1,255,496 | ||
|
Total operating expenses
|
1,633,791 | 1,449,640 | |||
|
Loss before provision for income taxes
|
(1,397,984) | (951,080) | |||
|
Other income (expense)
|
|||||
|
Interest income
|
17 | -- | |||
|
Other income
|
5,570 | -- | |||
|
Interest expense
|
(355,300) | (218,760) | |||
|
Total other income (expense)
|
(349,712) | (218,760) | |||
|
Provision for income taxes
|
-- | -- | |||
|
Net loss
|
$ | (1,747,696) | $ | (1,169,840) | |
|
Basic loss per common share
|
$ | (0.02) | $ | (0.02) | |
|
Basic weighted average common shares outstanding
|
89,034,972 | 77,675,313 | |||
See Accompanying Notes to Consolidated Financial Statements
|
Common Stock
|
Additional
Paid-in
|
Accumulated
|
Total
Stockholders' |
|||||||||||
|
Shares
|
Amount
|
Capital
|
Deficit
|
Deficit
|
||||||||||
|
Balance, December 31, 2008
|
84,095,888 | 84,098 | 16,552,571 | (16,937,725) | (301,056) | |||||||||
|
Issuance of stock for cash
|
575,000 | 575 | 25,425 | 26,000 | ||||||||||
|
Issaunce of stock for services
|
355,000 | 355 | 28,945 | 29,300 | ||||||||||
|
Issuance of stock for conversion of debts
|
7,673,692 | 7,673 | 269,647 | 277,320 | ||||||||||
|
Issuance of stock for accounts payable
|
2,243,929 | 2,244 | 284,372 | 286,616 | ||||||||||
|
Issuance of employee stock optrions
|
- | 261,044 | 261,044 | |||||||||||
|
Issuance of stock options/warrants for services
|
- | 296,410 | 296,410 | |||||||||||
| Beneficial conversion feature of convertible debt | - | 22,500 | 22,500 | |||||||||||
|
Net loss
|
- | (1,747,696) | (1,747,696) | |||||||||||
|
Balance, Decemer 31, 2009
|
94,943,509 | 94,945 | 17,740,914 | (18,685,421) | (849,562) | |||||||||
See Accompanying Notes to Consolidated Financial Statements
|
For the year ended
|
|||||
|
December 31, 2009
|
December 31, 2008
|
||||
|
Cash flows from operating activities:
|
|||||
|
Net loss
|
$ | (1,747,696) | $ | (1,640,877) | |
|
Adjustments to reconcile net loss to net cash used by operating activities:
|
|||||
|
Depreciation and amortization
|
25,755 | 17,536 | |||
|
Stock based compensation
|
625,686 | 437,892 | |||
|
Interest expense paid with common stock
|
234,524 | 199,151 | |||
|
Loss on disposal of assets
|
3,413 | 1,927 | |||
|
Changes in operating assets and liabilities:
|
|||||
|
(Increase) decrease in inventory
|
167 | 2,658 | |||
|
(Increase) decrease in accounts receivable
|
9,085 | 32,535 | |||
|
Decrease in prepaid expenses and other current assets
|
55,532 | 955 | |||
|
(Increase) decrease in related party receivable
|
(3,220) | 210 | |||
|
Decrease in prepaid royalty fees
|
180,000 | 240,000 | |||
|
Increase in accounts payable and accrued liabilities
|
272,565 | 144,397 | |||
|
Increase (decrease) in accrued interest
|
(6,110) | 16,261 | |||
|
(Decrease) in unearned revenue
|
(208) | (400,000) | |||
|
Net cash used in operating activities
|
(350,507) | (947,355) | |||
|
Cash flows from investing activities:
|
|||||
|
Purchase of fixed assets and intangible assets
|
(129,536) | (2,076) | |||
|
Net cash used in investing activities
|
(129,536) | (2,076) | |||
|
Cash flows from financing activities:
|
|||||
|
Proceeds from issuance of stock
|
26,000 | - | |||
|
Proceeds from, net of payments to, related parties for loans
|
91,349 | (76,724) | |||
|
Proceeds from convertible notes payable
|
75,000 | 846,548 | |||
|
Proceeds from loans
|
307,500 | 122,500 | |||
|
Net cash provided by financing activities
|
499,849 | 892,324 | |||
|
Net change in cash
|
19,806 | (57,107) | |||
|
Cash, beginning of period
|
6,062 | 63,168 | |||
|
Cash, end of period
|
$ | 25,868 | $ | 6,061 | |
SKINVISIBLE, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(AUDITED)
|
1.
|
DESCRIPTION OF BUSINESS, HISTORY AND SUMMARY OF SIGNIFICANT POLICIES
|
Description of business - Skinvisible, Inc., (referred to as the “Company”) is focused on the development and manufacture of innovative topical polymer-based delivery system technologies and formulations incorporating its patent-pending formula/process for combining hydrophilic and hydrophobic polymer emulsions. The technologies and formulations have broad industry applications within the pharmaceutical, over-the-counter, personal skincare and cosmetic arenas. The Company’s antibacterial/antimicrobial hand sanitizer formulations, available for private label commercialization opportunities, offer skincare solutions for the healthcare, food service, industrial, cosmetic and salon industries, as well as for personal use in the retail marketplace. The Company maintains manufacturing, executive and sales offices in Las Vegas, Nevada.
History - Skinvisible, Inc. ( referred to as the “Company”) was incorporated in Nevada on March 6, 1998 under the name of Microbial Solutions, Inc. The Company underwent a name change on February 26, 1999, when it changed its name to Skinvisible, Inc. The Company’s subsidiary’s name of Manloe Labs, Inc. was also changed to Skinvisible Pharmaceuticals, Inc.
Skinvisible, Inc. together with its subsidiary shall herein be collectively referred to as the “Company”.
Going concern - The accompanying financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. The Company has incurred cumulative net losses of $18,685,421 since its inception and requires capital for its contemplated operational and marketing activities to take place. The Company’s ability to raise additional capital through the future issuances of common stock is unknown. The obtainment of additional financing, the successful development of the Company’s contemplated plan of operations, and its transition, ultimately, to the attainment of profitable operations are necessary for the Company to continue operations. The ability to successfully resolve these factors raise substantial doubt about the Company’s ability to continue as a going concern. The consolidated financial statements of the Company do not include any adjustments that may result from the outcome of these aforementioned uncertainties.
Principles of consolidation - The consolidated financial statements include the accounts of the Company and its subsidiary. All significant intercompany balances and transactions have been eliminated.
Use of estimates - The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.
Revenue recognition
Product sales - Revenues from the sale of products are recognized when title to the products are transferred to the customer and only when no further contingencies or material performance obligations are warranted, and thereby have earned the right to receive reasonably assured payments for products sold and delivered.
Royalty sales – The Company also recognizes royalty revenue from licensing its patent and trademarks, only when earned, with no further contingencies or material performance obligations are warranted, and thereby have earned the right to receive and retain reasonably assured payments.
Distribution and license rights sales – The Company also recognizes revenue from distribution and license rights only when earned, with no further contingencies or material performance obligations are warranted, and thereby have earned the right to receive and retain reasonably assured payments.
Costs of Revenue – Cost of revenue includes raw materials, component parts, and shipping supplies. Shipping and handling costs is not a significant portion of the cost of revenue.
SKINVISIBLE, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(AUDITED)
Accounts Receivable – Accounts receivable is comprised of uncollateralized customer obligations due under normal trade terms requiring payment within 30 days from the invoice date. The carrying amount of accounts receivable is reviewed periodically for collectability. If management determines that collection is unlikely, an allowance that reflects management’s best estimate of the amounts that will not be collected is recorded. Management reviews each accounts receivable balance that exceeds 30 days from the invoice date and, based on an assessment of creditworthiness, estimates the portion, if any, of the balance that will not be collected. As of December 31, 2009, the Company had not recorded a reserve for doubtful accounts.
Inventory - Substantially all inventory consists of finished goods and are valued based upon first-in first-out ("FIFO") cost, not in excess of market. The determination of whether the carrying amount of inventory requires a write-down is based on an evaluation of inventory.
Goodwill and intangible assets - The Company follows Financial Accounting Standard Board’s (FASB) Codification Topic 350-10 (“ASC 350-10”), “Intangibles – Goodwill and Other”. According to this statement, goodwill and intangible assets with indefinite lives are no longer subject to amortization, but rather an annual assessment of impairment by applying a fair-value based test. Fair value for goodwill is based on discounted cash flows, market multiples and/or appraised values as appropriate. Under ASC 350-10, the carrying value of assets are calculated at the lowest level for which there are identifiable cash flows.
ASC 350-10 requires the Company to compare the fair value of the reporting unit to its carrying amount on an annual basis to determine if there is potential impairment. If the fair value of the reporting unit is less than its carrying value, an impairment loss is recorded to the extent that the fair value of the goodwill within the reporting unit is less than its carrying value. During 2009, the Company completed an impairment review and did not recognize any impairment of goodwill and other intangible assets already included in the financial statements. The Company expects to receive future benefits from previously acquired goodwill over an indefinite period of time. Accordingly, beginning January 1, 2002, the Company has foregone all related amortization expense. Prior to January 1, 2002, the Company amortized goodwill over an estimated useful life ranging from 3 to 15 years using the straight-line method.
Income taxes - The Company accounts for its income taxes in accordance with FASB Codification Topic ASC 740-10, “Income Taxes”, which requires recognition of deferred tax assets and liabilities for future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and tax credit carry-forwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date.
Stock-based compensation – The Company follows the guidelines in FASB Codification Topic ASC 718-10 “Compensation-Stock Compensation”, which requires the measurement and recognition of compensation expense for all share-based payment awards made to employees and directors including employee stock options and employee stock purchases related to a Employee Stock Purchase Plan based on the estimated fair values.
Stock based compensation expense recognized under ASC 718-10 for the years ended December 31, 2009 and 2008 totaled $625,686 and $372,626, respectively.
Earnings (loss) per share - The Company reports earnings (loss) per share in accordance with FASB Codification Topic ASC 260-10 “Earnings Per Share”, Basic earnings (loss) per share is computed by dividing income (loss) available to common shareholders by the weighted average number of common shares available. Diluted earnings (loss) per share is computed similar to basic earnings (loss) per share except that the denominator is increased to include the number of additional common shares that would have been outstanding if the potential common shares had been issued and if the additional common shares were dilutive. Diluted earnings (loss) per share has not been presented since the effect of the assumed exercise of options and warrants to purchase common shares (common stock equivalents) would have an anti-dilutive effect.
Reclassification – The financial statements from 2008 reflect certain reclassifications, which will have no effect on net income, to conform to classifications in the current year.
SKINVISIBLE, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(AUDITED)
Recent Accounting Pronouncements –
On May 28, 2009 the Financial Accounting Standards Board (FASB) issued FASB Accounting Standards Codification Topic (ASC) ASC 855-10, “Subsequent Events”. FASB ASC 855-10 should not result in significant changes in the subsequent events that an entity reports. Rather, FASB ASC 855-10 introduces the concept of financial statements being available to be issued. Financial statements are considered available to be issued when they are complete in a form and format that complies with generally accepted accounting principles (GAAP) and all approvals necessary for issuance have been obtained.
In June 2009, the FASB issued FASB ASC 105-10, The FASB Accounting Standards Codification and the Hierarchy of Generally Accepted Accounting Principles, which establishes the FASB Accounting Standards Codification™ (the Codification) as the source of authoritative accounting principles recognized by the FASB to be applied by nongovernmental entities in the preparation of financial statements in conformity with generally accepted accounting principles (GAAP), aside from those issued by the SEC. The Codification became effective for interim and annual periods ending after September 15, 2009. The Company adopted the Codification when referring to GAAP for the fiscal period ending September 30, 2009. The adoption of the Codification did not have an impact on the Company’s financial position or results of operations.
In January 2010, the FASB issued Accounting Standards Update 2010-02, “Consolidation (Topic 810): Accounting and Reporting for Decreases in Ownership of a Subsidiary”. This amendment to Topic 810 clarifies, but does not change, the scope of current US GAAP. It clarifies the decrease in ownership provisions of Subtopic 810-10 and removes the potential conflict between guidance in that Subtopic and asset derecognition and gain or loss recognition guidance that may exist in other US GAAP. An entity will be required to follow the amended guidance beginning in the period that it first adopts FAS 160 (now included in Subtopic 810-10). For those entities that have already adopted FAS 160, the amendments are effective at the beginning of the first interim or annual reporting period ending on or after December 15, 2009. The amendments should be applied retrospectively to the first period that an entity adopted FAS 160. The Company does not expect the provisions of ASU 2010-02 to have a material effect on the financial position, results of operations or cash flows of the Company.
In January 2010, the FASB issued Accounting Standards Update 2010-01, “Equity (Topic 505): Accounting for Distributions to Shareholders with Components of Stock and Cash (A Consensus of the FASB Emerging Issues Task Force)”. This amendment to Topic 505 clarifies the stock portion of a distribution to shareholders that allows them to elect to receive cash or stock with a limit on the amount of cash that will be distributed is not a stock dividend for purposes of applying Topics 505 and 260. Effective for interim and annual periods ending on or after December 15, 2009, and would be applied on a retrospective basis. The Company does not expect the provisions of ASU 2010-01 to have a material effect on the financial position, results of operations or cash flows of the Company.
|
2.
|
FIXED ASSETS
|
Fixed assets consist of the following as of December 31, 2009:
|
Machinery and equipment
|
$ | 55,463 |
|
Furniture and fixtures
|
113,635 | |
|
Computers, equipment and software
|
58,105 | |
|
Leasehold improvements
|
12,569 | |
|
Lab equipment
|
115,946 | |
| 335,718 | ||
|
Less: accumulated depreciation
|
326,202 | |
|
Fixed assets, net of accumulated depreciation
|
$ | 9,516 |
Depreciation expense for the years ending December 31, 2009 and 2008 was $5,394 and $5,996, respectively.
SKINVISIBLE, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(AUDITED)
|
3.
|
INTANGIBLE AND OTHER ASSETS
|
Patents and trademarks are capitalized at its historical cost and are amortized over their useful lives. As of December 31, 2009, patents and trademarks total $204,430, net of $71,922 of accumulated amortization. Amortization expense for the years ended December 31, 2009 and 2008 were $20,361 and $10,963, respectively.
License and distributor rights (“agreement”) was acquired by the Company in January 1999 and provides exclusive use distribution of polymers and polymer based products. The Company has a non-expiring term on the license and distribution rights. Accordingly, the Company annually assesses this license and distribution rights for impairment and has determined that no impairment write-down is considered necessary as of December 31, 2009.
Prepaid royalties fees are amounts prepaid by the Company related to the license and distributor rights. The future royalties payments required by the Company total $2,000,000. The royalties fees are to be paid in an amount equal to the greater of (a) $6,000 per month; or (b) 1.5% of net revenues realized by the sale of the associated polymer products subject to a cap of $2,000,000. The Company will make payments of $6,000 per month, and by a payment on any royalties in excess of $72,000 in each year payable on an annual basis calculated within 60 days of each anniversary date of the agreement. The future royalties payments are to be amortized over eight years, which is the life of the agreement. As of December 31, 2009, the Company has paid a total of $2,000,000 of which $2,000,000 has been expensed.
|
4.
|
UNEARNED REVENUE
|
Unearned revenue totaling $49,792 as of December 31, 2009 relates to a marketing and distribution rights agreement entered into during 2009 for which monies were received and not considered earned.
|
5.
|
STOCK OPTIONS AND WARRANTS
|
Stock options employees and directors – During the years ended December 31, 2009 and 2008, the Company granted stock options to employees and directors totaling 3,920,000 and 3,295,000 shares of its common stock with a weighted average strike price of $0.06 and $0.09 per share, respectively. Certain stock options were exercisable upon grant and have a life ranging from 3 months to 5 years. The stock options have been valued at $299,370 and $232,892 for 2009 and 2008, respectively, using the Black-Scholes option pricing model based upon the following assumptions: term of 5 years, risk free interest rates ranging from 2.19% to 3%, a dividend yield of 0% and volatility rates ranging from 131% to 167%. The Company has recorded an expense of $299,370 and $68,912 for the years ended December 31, 2009 and 2008, respectively.
Stock options non-employees – During the years ended December 31, 2009 and 2008, the Company granted stock options for services totaling 200,000 and 875,000 shares of its common stock with a weighted average strike price of $0.04 and $0.13 per share, respectively. All stock options were exercisable upon grant. The stock options have been valued at $12,160 during 2009 and $120,086 during 2008 using the Black-Scholes option pricing model based upon the following assumptions: term of 5 years, risk free interest rates ranging from 3.5% to 4.5%, a dividend yield of 0% and volatility rates ranging from 103% to 131%.
SKINVISIBLE, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(AUDITED)
The following is a summary of option activity during the years ended December 31, 2009 and 2008:
|
Number of Shares
|
Weighted Average Exercise Price
|
||||
|
Balance, December 31, 2007
|
5,515,000 | 0.17 | |||
|
Options granted and assumed
|
4,170,000 | 0.24 | |||
|
Options expired
|
1,690,000 | 0.18 | |||
|
Options canceled
|
- | 0 | |||
|
Options exercised
|
1,200,000 | 0.05 | |||
|
Balance, December 31, 2008
|
6,795,000 | 0.14 | |||
|
Options granted and assumed
|
4,120,000 | 0.06 | |||
|
Options expired
|
1,670,000 | 0.13 | |||
|
Options canceled
|
- | ||||
|
Options exercised
|
275,000 | 0.04 | |||
|
Balance, December 31, 2009
|
8,970,000 | 0.05 | |||
As of December 31, 2009, 8,970,000 stock options are exercisable.
Stock warrants -
The following is a summary of warrants activity during the years ended December 31, 2009 and 2008:
|
Number of Shares
|
Weighted Average Exercise Price
|
||||
|
Balance, December 31, 2007
|
4,231,500 | 0.15 | |||
|
Warrants granted and assumed
|
6,437,500 | 0.10 | |||
|
Warrants expired
|
1,820,000 | 0.14 | |||
|
Warrants canceled
|
- | 0.00 | |||
|
Warrants exercised
|
500,000 | 0.05 | |||
|
Balance, December 31, 2008
|
8,349,000 | 0.16 | |||
|
Warrants granted and assumed
|
2,336,847 | 0.07 | |||
|
Warrants expired
|
637,500 | 0.29 | |||
|
Warrants canceled
|
1,474,000 | 0.10 | |||
|
Warrants exercised
|
287,500 | 0.13 | |||
|
Balance, December 31, 2009
|
8,286,847 | 0.10 | |||
All warrants outstanding as of December 31, 2009 are exercisable.
SKINVISIBLE, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(AUDITED)
|
6.
|
RELATED PARTY TRANSACTIONS
|
As of December 31, 2008, the Company had an unsecured loan payable due to the CEO with an interest rate of 10% per annum, due on demand totaling $2,136, and an unsecured loan payable due to an employee under similar terms in the amount of $120,627.
As of December 31, 2009, the Company had an unsecured loan payable due to an employee with an interest rate of 10% per annum, due on demand totaling $214,112.
|
7.
|
CONVERTIBLE NOTES PAYABLE
|
During 2009, the Company issued an aggregate of $382,500 consisting of promissory convertible notes to eight individuals. One of the notes is due by January 12, 2010, accruing interest at 10% per annum. At the investor’s option until the repayment date, the note can be converted to shares of the Company’s common stock at a fixed price of $0.10 per share along with additional warrants to purchase one share per every two shares issued at the exercise price of $0.15 per share for two years after the conversion date. As of December 31, 2009, all but one of the notes, with a total face value of $307,500, were converted into 7,613,692 shares.
The Company has determined the value associated with the conversion feature in connection with the remaining convertible note payable. The Company has determined the note, with a face value of $75,000, to have a beneficial conversion feature totaling $22,500. The beneficial conversion feature has been accreted and charged to interest expense in the amount of $18,750 as of December 31, 2009. The beneficial conversion feature is valued under the intrinsic value method.
|
8.
|
COMMITMENTS AND CONTINGENCIES
|
Lease obligations – The Company has operating leases for its offices. Future minimum lease payments under the operating leases for the facilities as of December 31, 2009 are as follows:
|
2010
|
$ | 48,005 |
|
2011
|
57,606 | |
|
2012
|
57,606 |
Rental expense, resulting from operating lease agreements, approximated $113,537 for the year ended December 31, 2009.
Lawsuit – The Company is the defendant in a lawsuit brought by a former member of the Board of Directors. The lawsuit claims that certain expenses and a loan in the amount of $20,000 were not repaid to the plaintiff. The Company is disputing these allegations. It is not possible to determine a probable outcome at this time, and since Company management feels a material loss from this suit to be remote, the Company has not accrued any related expenses.
|
9.
|
SUBSEQUENT EVENTS
|
None.
The Company has evaluated subsequent events through March 31, 2010, the date which the financial statements were available to be issued.
Item 9. Changes In and Disagreements with Accountants on Accounting and Financial Disclosure
No events occurred requiring disclosure under Item 307 and 308 of Regulation S-K during the fiscal year ending December 31, 2009.
Item 9A(T). Controls and Procedures
We carried out an evaluation of the effectiveness of the design and operation of our disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) as of December 31, 2009. This evaluation was carried out under the supervision and with the participation of our Chief Executive Officer and Chief Financial Officer, Mr. Terry Howlett. Based upon that evaluation, our Chief Executive Officer and Chief Financial Officer concluded that, as of December 31, 2009, our disclosure controls and procedures are effective. There have been no significant changes in our internal controls over financial reporting during the quarter ended December 31, 2009 that have materially affected or are reasonably likely to materially affect such controls.
Disclosure controls and procedures are controls and other procedures that are designed to ensure that information required to be disclosed in our reports filed or submitted under the Exchange Act are recorded, processed, summarized and reported, within the time periods specified in the SEC's rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed in our reports filed under the Exchange Act is accumulated and communicated to management, including our Chief Executive Officer and Chief Financial Officer, to allow timely decisions regarding required disclosure.
Limitations on the Effectiveness of Internal Controls
Our management does not expect that our disclosure controls and procedures or our internal control over financial reporting will necessarily prevent all fraud and material error. Our disclosure controls and procedures are designed to provide reasonable assurance of achieving our objectives and our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures are effective at that reasonable assurance level. Further, the design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within our company have been detected. These inherent limitations include the realities that judgments in decision-making can be faulty, and that breakdowns can occur because of simple error or mistake. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people, or by management override of the internal control. The design of any system of controls also is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions. Over time, control may become inadequate because of changes in conditions, or the degree of compliance with the policies or procedures may deteriorate.
Management’s Annual Report on Internal Control over Financing Reporting
Our management is responsible for establishing and maintaining adequate control over financial reporting, as such term is defined in Rules 13a-15(f) and 15d-15(f) under the Securities Exchange Act of 1934. Under the supervision and with the participation of our principal executive and principal financial officer, we conducted an evaluation of the effectiveness of our internal control over financial reporting based on the framework in Internal Control - Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (the “COSO Framework”). Based on this evaluation under the COSO Framework, management concluded that its internal control over financial reporting was effective as of December 31, 2009.
This annual report does not include an attestation report of our registered public accounting firm regarding internal control over financial reporting. Management’s report was not subject to attestation by our registered public accounting firm pursuant to temporary rules of the Securities and Exchange Commission that permit us to provide only management’s report in this annual report.
Item 9B. Other Information
None
PART III
Item 10. Directors, Executive Officers and Corporate Governance
The following information sets forth the names, ages, and positions of our current directors and executive officers as of December 31, 2009.
|
Name
|
Age
|
Position(s) and Office(s) Held
|
|
Terry Howlett
|
62
|
Chief Executive Officer, Chief Financial Officer, & Director
|
|
Brian Piwek
|
63
|
Director
|
|
Greg McCartney
|
59
|
Director
|
Set forth below is a brief description of the background and business experience of each of our current executive officers and directors.
Mr. Terry H. Howlett, has been our Chief Executive Officer & Director since March 5, 1998. Mr. Howlett has a diversified background in market initialization and development, sales and venture capital financing for emerging growth companies. He has held senior management, marketing and sales positions with various companies, including the Canadian Federation of Independent Business, Family Life Insurance, and Avacare of Canada and founded Presley Laboratories, Inc., which marketed cosmetic and skin, care products on a direct sales basis. For the ten years prior to becoming President of the Company, Mr. Howlett was the President and CEO of Voice-it Solutions, Inc., a publicly traded company on the Vancouver Stock exchange that made voice response software for order entry systems.
Mr. Brian Piwek joined our board of directors in January, 2008. Mr. Piwek's experience and expertise is in the international retail industry. He was president of Overwaitea Foods supermarket from 1991 until 1997. In 1997 Brian accepted the position as Co-CEO with A&P Canada (The Great Atlantic & Pacific Tea Company Inc.) and in 2000 was appointed Chairman, President and CEO of A&P Canada. In late 2002 he moved to the U.S. as President and Chief Executive Officer of A&P US (New York Stock Exchange symbol "GAP") where he began the turnaround of North America's oldest retail food chain. Brian retired from A&P in July 2005. Brian is an MBA graduate and has served on many voluntary boards.
Mr. Greg McCartney has been a member of our board of directors since January 10, 2005. Mr. McCartney is Managing Director of Taylor, Butterfield & Worth Asset Management Corporation, a management consulting services firm assisting clients in becoming fully reporting public companies. Previously Mr. McCartney was the Chairman of the Board for Genesis Bioventures (formely BioLabs) and also formerly served as their CEO. Mr. McCartney has over 20 years experience serving as officer and director of both private and public companies in various manufacturing and technology industries. Prior to founding BioLabs in 1997, Mr. McCartney was the founder and director of Aspenwood Holdings Corporation, a business consulting firm specializing in financing, public relations and venture capital in the technology and manufacturing industries. From 1986 to 1995 he was the President of an emerging high technology company and also served as officer and director of other companies. Previously, he was involved with international real estate and land development.
Directors
Our bylaws authorize no less than one (1) and more than ten (12) directors. We currently have three Directors.
Term of Office
Our Directors are appointed for a one-year term to hold office until the next annual general meeting of our shareholders or until removed from office in accordance with our bylaws. Our officers are appointed by our board of directors and hold office until removed by the board.
Significant Employees
Ms. Doreen McMorran, is head of Business Development. Ms. McMorran brings to the Company almost 20 years of experience in the medical and pharmaceutical industry, specifically in the areas of strategic planning, sales and marketing. She has spent the last seven years selling to international dermatology and skincare focused companies like Procter and Gamble, Johnson & Johnson, Stiefel, Galderma, Novartis and Graceway, to name a few. Ms. McMorran, who holds a Bachelor of Commerce (Honours) degree, spent six years in the pharmaceutical industry with Astra Pharma. Additionally she has held senior management level positions with a number of healthcare companies, focusing on business development, sales, marketing and operations.
Dr. James A. Roszell, Ph.D, is a doctoral chemist with over 35 years' experience in product formulation, experimental design, analysis, and method validation. Since joining Skinvisible in 1998, he has been responsible for research and development of our patented technology, related polymer delivery vehicles, product formulations and compositions. Dr. Roszell is a joint contributor to Skinvisible's Patent Number 6.756.059 and responsible for our nine pending patents in the US. Prior to joining Skinvisible, he worked as chemist for Supertech Products, Inc. in Florida where his responsibilities included ensuring compliance with OSHA, EPA and other standards and regulations, maintenance of quality control, research and development for new products. Dr. Roszell's background includes work in chemical, pharmaceutical, environmental and clinical laboratory arenas. His chemical and scientific expertise makes a significant contribution to our business.
Family Relationships
There are no family relationships between or among the directors, executive officers or persons nominated or chosen by us to become directors or executive officers.
Involvement in Certain Legal Proceedings
To the best of our knowledge, during the past five years, none of the following occurred with respect to a present or former director, executive officer, or employee: (1) any bankruptcy petition filed by or against any business of which such person was a general partner or executive officer either at the time of the bankruptcy or within two years prior to that time; (2) any conviction in a criminal proceeding or being subject to a pending criminal proceeding (excluding traffic violations and other minor offenses); (3) being subject to any order, judgment or decree, not subsequently reversed, suspended or vacated, of any court of competent jurisdiction, permanently or temporarily enjoining, barring, suspending or otherwise limiting his or her involvement in any type of business, securities or banking activities; and (4) being found by a court of competent jurisdiction (in a civil action), the SEC or the Commodities Futures Trading Commission to have violated a federal or state securities or commodities law, and the judgment has not been reversed, suspended or vacated.
Audit Committee
We do not have a separately-designated standing audit committee. The entire board of directors performs the functions of an audit committee, but no written charter governs the actions of the board of directors when performing the functions of that would generally be performed by an audit committee. The board of directors approves the selection of our independent accountants and meets and interacts with the independent accountants to discuss issues related to financial reporting. In addition, the board of directors reviews the scope and results of the audit with the independent accountants, reviews with management and the independent accountants our annual operating results, considers the adequacy of our internal accounting procedures and considers other auditing and accounting matters including fees to be paid to the independent auditor and the performance of the independent auditor.
We do not have an audit committee financial expert because of the size of our company and our board of directors at this time. We believe that we do not require an audit committee financial expert at this time because we retain outside consultants who possess these attributes as needed.
For the fiscal year ending December 31, 2009, the board of directors:
|
1.
|
Reviewed and discussed the audited financial statements with management, and
|
|
2.
|
Reviewed and discussed the written disclosures and the letter from our independent auditors on the matters relating to the auditor's independence.
|
Based upon the board of directors’ review and discussion of the matters above, the board of directors authorized inclusion of the audited financial statements for the year ended December 31, 2009 to be included in this Annual Report on Form 10-Kand filed with the Securities and Exchange Commission.
Section 16(a) Beneficial Ownership Reporting Compliance
Section 16(a) of the Exchange Act requires our directors and executive officers and persons who beneficially own more than ten percent of a registered class of the Company’s equity securities to file with the SEC initial reports of ownership and reports of changes in ownership of common stock and other equity securities of the Company. Officers, directors and greater than ten percent beneficial shareholders are required by SEC regulations to furnish us with copies of all Section 16(a) forms they file. To the best of our knowledge based solely on a review of Forms 3, 4, and 5 (and any amendments thereof) received by us during or with respect to the year ended December 31, 2009, the following persons have failed to file, on a timely basis, the identified reports required by Section 16(a) of the Exchange Act during fiscal year ended December 31, 2009:
|
Name and principal position
|
Number of
late reports
|
Transactions not
timely reported
|
Known failures to
file a required form
|
|
Terry Howlett
CEO, CFO & Director
|
0
|
2
|
1
|
|
Greg McCartney
Director
|
0
|
2
|
1
|
|
Brian Piwek
Director
|
0
|
2
|
1
|
Code of Ethics
We adopted a Code of Ethics for Financial Executives, which include our principal executive officer, principal financial officer, principal accounting officer or controller, or persons performing similar functions. The Code of Ethics was filed as an exhibit to the annual report on Form 10KSB for the fiscal year ended December 31, 2004 and filed with the SEC on April 14, 2005.
Compensation Discussion and Analysis
Currently, the objective of the cash compensation paid by the company is to provide fair reimbursement for the time spent by our executive officer and independent directors to the extent feasible within the financial constraints faced by our developing business. The stock options granted to our executive officer and to our independent directors are intended to provide these individuals with incentives to pursue the growth and development of the company’s operations and business opportunities. Although the options awarded to our executive and directors are typically exercisable immediately, they also remain valid and exercisable for terms of several years. We believe this provides the proper balance of short-term and long-term incentives to increase the value of the company. Although an immediate increase in share price following the issuance of the options would obviously result in a profit if those options were exercised, the longer exercisable period of the options also provides an incentive to increase value over the long term and gives our executive officer and directors the opportunity to realize gains based on the sustained growth of our operations and revenues.
In addition, our sole executive officer holds substantial ownership in the company and is generally motivated by a strong entrepreneurial interest in expanding our operations and revenue base to the best of his ability.
Summary Compensation Table
The table below summarizes all compensation awarded to, earned by, or paid to our former or current executive officers for the fiscal years ended December 31, 2009 and 2008.
| SUMMARY COMPENSATION TABLE | |||||||||
|
Name
and
principal
position
|
Year
|
Salary ($)
|
Bonus
($)
|
Stock
Awards
($)
|
Option
Awards
($)
|
Non-Equity
Incentive Plan
Compensation
($)
|
Nonqualified
Deferred
Compensation
Earnings ($)
|
All Other
Compensation
($)
|
Total
($)
|
|
Terry Howlett
CEO & CFO
|
2008
2009
|
160,000
160,000
|
-
-
|
-
-
|
110,000
75,304
|
-
-
|
-
-
|
-
-
|
270,000
235,304
|
Narrative Disclosure to the Summary Compensation Table
On January 29, 2009, we entered into an employment agreement with our sole executive officer, Terry Howlett. The agreement is effective retroactively to January 1, 2009, and term of the agreement is three (3) years. Unless extended or renewed, the agreement will terminate on January 1, 2012. Under the agreement, Mr. Howlett earns a cash stipend of $13,333.33 per month ($160,000 per year). Effective January 1, 2010, his cash stipend increased to $15,000 per month ($180,000 per year). He will also receive bonuses based on a percentage of license fees, royalty fees, and financings; paid vacation or the election to receive vacation benefits in payment; and reimbursements of expenses, including automobile and limited living expenses. In addition, the agreement provides for Mr. Howlett to be awarded stock options at the discretion of the board of directors.
Due to financial constraints, however, we were only able to actually pay Mr. Howlett $77,833 in cash during the fiscal year ended December 31, 2009.
During the fiscal year ended December 31, 2009, we granted Mr. Howlett options to purchase 1,000,000 shares of our common stock at the exercise price of $0.8 per share with an expiration date of December 7, 2014. These options are fully vested and immediately exercisable. The aggregate value of these options, which totaled $110,000, was computed in accordance with FAS 123R and is reported in the summary compensation table above in the column titled “Option Awards.”
Outstanding Equity Awards at Fiscal Year-End
The table below summarizes all unexercised options, stock that has not vested, and equity incentive plan awards for each named executive officer as of December 31, 2009.
|
OUTSTANDING EQUITY AWARDS AT FISCAL YEAR-END
|
|||||||||
|
OPTION AWARDS
|
STOCK AWARDS
|
||||||||
|
Name
|
Number of
Securities
Underlying
Unexercised
Options
(#)
Exercisable
|
Number of
Securities
Underlying
Unexercised
Options
(#)
Unexercisable
|
Equity
Incentive
Plan
Awards:
Number of
Securities
Underlying
Unexercised
Unearned
Options
(#)
|
Option
Exercise
Price
($)
|
Option
Expiration
Date
|
Number
of
Shares
or Units
of
Stock That
Have
Not
Vested
(#)
|
Market
Value
of
Shares
or
Units
of
Stock
That
Have
Not
Vested
($)
|
Equity
Incentive
Plan
Awards:
Number
of
Unearned
Shares,
Units or
Other
Rights
That Have
Not
Vested
(#)
|
Equity
Incentive
Plan
Awards:
Market or
Payout
Value of
Unearned
Shares,
Units or
Other
Rights
That
Have Not
Vested
(#)
|
|
Terry Howlett
|
1,000,000
400,000
200,000
1,000,000
1,000,000
|
-
-
-
-
-
|
-
-
-
-
-
|
0.04
0.04
0.04
0.04
0.08
|
10/19/2013
1/30/2013
1/3/2011
1/20/2014
12/7/2014
|
-
-
-
-
|
-
-
-
-
|
-
-
-
-
|
-
-
-
-
|
On April 21, 2009, we modified the exercise price on all of our outstanding options issued prior to March 31, 2009 to $0.04 per share, which included all options issued to Mr. Howlett aside from the option issued in December 7, 2009 of 1,000,000 shares at $0.08 per share. Aside from this modification, during the last fiscal year there was not any outstanding option repriced or otherwise modified. There was no tandem feature, reload feature, or tax-reimbursement feature associated with any of the stock options we granted to our executive officers or otherwise.
Director Compensation
The table below summarizes all compensation of our directors as of December 31, 2009.
|
DIRECTOR COMPENSATION
|
|||||||
|
Name
|
Fees Earned or
Paid in
Cash
($)
|
Stock Awards
($)
|
Option Awards
($)
|
Non-Equity
Incentive
Plan
Compensation
($)
|
Non-Qualified
Deferred
Compensation
Earnings
($)
|
All
Other
Compensation
($)
|
Total
($)
|
|
Greg McCartney
|
7,200
|
-
|
250,000
|
-
|
-
|
-
|
35,395
|
|
Brian Piwek
|
7,200
|
250,000
|
-
|
-
|
-
|
26,026
|
|
Narrative Disclosure to the Director Compensation Table
All the fees earned or paid in cash and stock options awards granted to Terry Howlett were earned in connection with his service as an executive officer. Mr. Howlett received no compensation for his service as a member of our board of directors.
We pay our independent directors a monthly fee of $600. Mr. McCartney received a total of $7,200 and Mr. Piwek received a total of $7,200 in consideration for services rendered as members of our board of directors in 2009. In addition, Mr. McCartney and Mr. Piwek each received options to purchase 250,000 shares of common stock at an exercise price of $0.08 per share and Mr. McCartney received a 5 year extension on previously issued options of 250,000 shares of common stock at an exercise price of $0.04 per share. These options are fully vested and immediately exercisable. The aggregate value of these options for Mr. McCartney is $28,195 and Mr. Piwek is $18,826 for each independent director, was computed in accordance with FAS 123R and is reported in the director compensation table above in the column titled “Option Awards.”
Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters
The following table sets forth certain information known to us with respect to the beneficial ownership of our Common Stock as of December 31, 2009, by (1) all persons who are beneficial owners of 5% or more of our voting securities, (2) each director, (3) each executive officer, and (4) all directors and executive officers as a group. The information regarding beneficial ownership of our common stock has been presented in accordance with the rules of the Securities and Exchange Commission. Under these rules, a person may be deemed to beneficially own any shares of capital stock as to which such person, directly or indirectly, has or shares voting power or investment power, and to beneficially own any shares of our capital stock as to which such person has the right to acquire voting or investment power within 60 days through the exercise of any stock option or other right. The percentage of beneficial ownership as to any person as of a particular date is calculated by dividing (a) (i) the number of shares beneficially owned by such person plus (ii) the number of shares as to which such person has the right to acquire voting or investment power within 60 days by (b) the total number of shares outstanding as of such date, plus any shares that such person has the right to acquire from us within 60 days. Including those shares in the tables does not, however, constitute an admission that the named stockholder is a direct or indirect beneficial owner of those shares. Unless otherwise indicated, each person or entity named in the table has sole voting power and investment power (or shares that power with that person’s spouse) with respect to all shares of capital stock listed as owned by that person or entity.
The following table sets forth, as of December 31, 2009, the beneficial ownership of our common stock by each executive officer and director, by each person known by us to beneficially own more than 5% of the our common stock and by the executive officers and directors as a group. Except as otherwise indicated, all shares are owned directly and the percentage shown is based on 94,943,509 shares of common stock issued and outstanding on December 31, 2009. Except as otherwise indicated, the address of each person named in this table is c/o Skinvisible, Inc., 6320 South Sandhill Road, Suite 10, Las Vegas, Nevada 89120.
|
Title of class
|
Name and address of beneficial owner (1)
|
Amount of beneficial ownership
|
Percent of class*
|
|
Executive Officers & Directors:
|
|||
|
Common
|
Terry Howlett
|
13,323,248 shares
|
13.25 (2)
|
|
Common
|
Brian Piwek
|
1,328,990 shares
|
1.38% (3)
|
|
Common
|
Greg McCartney
|
1,644,000 shares
|
1.71% (4)
|
|
Total of All Directors and Executive Officers:
|
16,296,238 shares
|
15.89%
|
|
| More Than 5% Beneficial Owners: | |||
| Lutz Family Trust
8322 West Tonto Lane, Peoria, AZ 85382(5)
|
|
11.70%
|
|
|
(1)
|
As used in this table, "beneficial ownership" means the sole or shared power to vote, or to direct the voting of, a security, or the sole or shared investment power with respect to a security (i.e., the power to dispose of, or to direct the disposition of, a security). In addition, for purposes of this table, a person is deemed, as of any date, to have "beneficial ownership" of any security that such person has the right to acquire within 60 days after such date.
|
|
(2)
|
Includes options that may be exercised immediately to purchase 2,600,000 shares at a price of $0.04 per share, options that may be exercised immediately to purchase 1,000,000 shares at $0.08 per share, warrants that may be immediately exercised to purchase 500,000 shares at a price of $0.15 per share, and warrants that may be immediately exercised to purchase 1,5000,000 shares at a price of $0.05 per share.
|
|
(3)
|
Includes options that may be immediately exercised to purchase 450,000 shares at a price of $0.04 per share, options that may be exercised immediately to purchase 250,000 shares at $0.08, and warrants that may be immediately exercised to purchase 125,000 at $0.12 per share.
|
|
(4)
|
Includes options that may be exercised immediately to purchase 900,000 shares at a price of $0.04 per share, and options that may be exercised immediately to purchase 250,000 shares at a price of $0.08 per share.
|
|
(5)
|
As stated in the reporting person’s Schedule 13D filed with the Securities and Exchange Commission on January 25, 2010.
|
Item 13. Certain Relationships and Related Transactions, and Director Independence
None of our directors or executive officers, nor any proposed nominee for election as a director, nor any person who beneficially owns, directly or indirectly, shares carrying more than 5% of the voting rights attached to all of our outstanding shares, nor any members of the immediate family (including spouse, parents, children, siblings, and in-laws) of any of the foregoing persons has any material interest, direct or indirect, in any transaction since the beginning of our last fiscal year on January 1, 2009 or in any presently proposed transaction which, in either case, has or will materially affect us.
Our policy regarding related transactions requires that any director or officer who has an interest in any transaction disclose the presence and the nature of the interest to the board of directors prior to any approval of the transaction by the board of directors. The transaction may then be approved by a majority of the disinterested directors, provided that an interested director may be counted in determining the presence of a quorum at the meeting of the board of directors to approve the transaction.
As of December 31, 2009, the Company had an unsecured loan payable due to Terry Howlett with an interest rate of 10% per annum, due on demand totaling $68,360.
As of December 31, 2009, the Company had a receivable due to it from Terry Howlett totaling $1,196.
As of December 31, 2009, the Company had an unsecured loan payable due to Terry Howlett with an interest rate of 10% per annum, due on demand totaling $2,136.
Item 14. Principal Accounting Fees and Services
Below is the table of Audit Fees (amounts in US$) billed by our auditor in connection with the audit of the Company’s annual financial statements for the years ended:
|
Financial Statements for the Year Ended December 31
|
Audit Services
|
Audit Related Fees
|
Tax Fees
|
Other Fees
|
|
2008
|
$27,170
|
$0
|
$0
|
$0
|
|
2009
|
$25,010
|
$0
|
$0
|
$0
|
PART IV
Item 15. Exhibits, Financial Statements Schedules
|
Exhibit Number
|
Description
|
|
3.1
|
Articles of Incorporation, as amended (1)
|
|
3.2
|
Bylaws, as amended (1)
|
|
3.3
|
Certificate of Amendment to The Company’s Articles of Incorporation(2)
|
|
14.1
|
Code of Ethics (3)
|
|
1
|
Incorporated by reference to the Registration Statement on Form 10SB12G filed on April; 30, 1999.
|
|
2
|
Incorporated by reference to the Report on Form 8-K filed on September 12, 2008.
|
|
3
|
Incorporated by reference to Current report on Form 10-KSB filed with the Securities and Exchange Commission on April 14, 2005.
|
SIGNATURES
In accordance with Section 13 or 15(d) of the Exchange Act, the registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
Skinvisible, Inc.
|
By:
|
/s/ Terry Howlett
|
|
Terry Howlett
President, Chief Executive Officer, Principal Executive Officer,
Chief Financial Officer, Principal Financial Officer, Principal Accounting Officer and Director
|
|
|
April 14, 2010
|
In accordance with Section 13 or 15(d) of the Exchange Act, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated:
|
By:
|
/s/ Terry Howlett
|
|
Terry Howlett
|
|
|
Director
|
|
|
April 14, 2010
|
|
|
By:
|
/s/ Brian Piwek |
|
Brian Piwek
|
|
|
Director
|
|
|
April 14, 2010
|
|
|
By:
|
/s/ Greg McCartney |
|
Greg McCartney
|
|
|
Director
|
|
|
April 14, 2010
|